Approval · Notice of Compliance 37087 · 2026
REACTINE: Notice of Compliance 37087
Issued March 12, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37087
- Date
- March 12, 2026
- Company
- Kenvue Canada Inc.Guelph, Ontario, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Administrative: Change in manufacturer name
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REACTINE | 02223546 | Marketed |
| REACTINE | 02223554 | Marketed |
| REACTINE | 02238337 | Marketed |
| REACTINE ALLERGY | 02486954 | Marketed |
| REACTINE ALLERGY LIQUID GELS | 02368064 | Marketed |
| REACTINE FAST MELT JUNIOR | 02358352 | Marketed |
| REACTINE RAPID DISSOLVE | 02467577 | Marketed |
Medicinal ingredients
- CETIRIZINE HYDROCHLORIDE 5 MG per TAB
- CETIRIZINE HYDROCHLORIDE 10 MG per TAB
- CETIRIZINE HYDROCHLORIDE 5 MG per 5ML
- CETIRIZINE HYDROCHLORIDE 10 MG per CAP